Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT00626106 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT00626106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Lead sponsor
NantCell, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2008
Completion date
September 23, 2011
Enrollment
156 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast tumors, metastatic cancer